Age-Specific Survival in Lung Cancer in the Nordic Countries through a Half Century

Kari Hemminki*; Frantisek Zitricky; Asta Fu00f6rsti; Otto Hemminki; Akseli Hemminki

**Kari Hemminki*, Frantisek Zitricky, Asta Fu00f6rsti, Otto Hemminki, and Akseli Hemminki**

Volume5-Issue8
Dates: Received: 2024-08-07 | Accepted: 2024-08-20 | Published: 2024-08-21
Pages: 996-1005

Abstract

Background: Lung cancer (LC) is often diagnosed at a late stage in relatively old persons whose survival may be compromised because of limited treatment. Our aim was to carry out an age-specific survival study on LC in Denmark (DK), Finland (FI), Norway (NO) and Sweden (SE) through a half century (1972-2021). Nordic survival data were compared with survival in the US Surveillance, Epidemiology and End Results (SEER) database

Methods: Relative 1- and 5-year survival data were extracted from the NORDCAN database and subjected to modelling by generalized additive models for survival trends over time. Conditional survival was calculated for those who had survived the first year to survive additional 4 years

Results: Very little improvement was found in survival for any age group before year 2000. By 2017-21, 5-year survival for men below age 50 years has increased to over 40% (FI somewhat less) and for equally aged women it was over 50% in countries other than FI. Survival reached over 20% for the 80-89-year-old male and female patients but it was 7% for men and 12% for women in FI. DK age-group-specific survival curves stayed well parallel to each other indicating equal improvement but for FI and SE men the curves diverged showing increasing age gaps. Nordic age-specific survival data were better than those in the US SEERS

Conclusion: Survival increased, after a 30-year standstill, after 2000 with increasing tempo towards 2017-21 and encompassing all age groups. This and the increase in conditional survival suggested that even the oldest patients were offered effective treatment. As LC remains a fatal disease all prevention modes needs to be emphasized, starting from primary prevention, to early detection and therapeutic improvements.

FullText HTML FullText PDF DOI: 10.37871/jbres1980

Certificate of Publication

Copyright

How to cite this article

Hemminki K, Zitricky F, Försti A, Hemminki O, Hemminki A. Age-Specifi c Survival in Lung Cancer in the Nordic Countries through a Half Century. J Biomed Res Environ Sci. 2024 Aug 21; 5(8): 996-1005. doi: 10.37871/jbres1980, Article ID: JBRES1980, Available at: https://www.jelsciences.com/articles/jbres1980.pdf

Subject area(s)

Oncology

Cancer

References

Islami F, Torre LA, Jemal A. Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res. 2015 Aug;4(4):327-38. doi: 10.3978/j.issn.2218-6751.2015.08.04. PMID: 26380174; PMCID: PMC4549470.
Thun M, Peto R, Boreham J, Lopez AD. Stages of the cigarette epidemic on entering its second century. Tob Control. 2012 Mar;21(2):96-101. doi: 10.1136/tobaccocontrol-2011-050294. PMID: 22345230.
Lipfert FW, Wyzga RE. Longitudinal relationships between lung cancer mortality rates, smoking, and ambient air quality: a comprehensive review and analysis. Crit Rev Toxicol. 2019 Oct;49(9):790-818. doi: 10.1080/10408444.2019.1700210. Epub 2020 Jan 27. PMID: 31985340.
Hemminki K, Försti A, Hemminki A, Ljungberg B, Hemminki O. Incidence trends in lung and bladder cancers in the Nordic Countries before and after the smoking epidemic. Eur J Cancer Prev. 2022 May 1;31(3):228-234. doi: 10.1097/CEJ.0000000000000694. PMID: 34074862.
Turner MC, Andersen ZJ, Baccarelli A, Diver WR, Gapstur SM, Pope CA 3rd, Prada D, Samet J, Thurston G, Cohen A. Outdoor air pollution and cancer: An overview of the current evidence and public health recommendations. CA Cancer J Clin. 2020 Aug 25:10.3322/caac.21632. doi: 10.3322/caac.21632. Epub ahead of print. PMID: 32964460; PMCID: PMC7904962.
Frank C, Fallah M, Ji J, Sundquist J, Hemminki K. The population impact of familial cancer, a major cause of cancer. Int J Cancer. 2014 Apr 15;134(8):1899-906. doi: 10.1002/ijc.28510. Epub 2013 Oct 31. PMID: 24590453.
Liu X, Hemminki K, Försti A, Sundquist K, Sundquist J, Ji J. Cancer risk in patients with type 2 diabetes mellitus and their relatives. Int J Cancer. 2015 Aug 15;137(4):903-10. doi: 10.1002/ijc.29440. Epub 2015 Feb 5. PMID: 25604005.
Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K, Silverman DT, Znaor A, Catto JWF. Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. Eur Urol. 2018 Dec;74(6):784-795. doi: 10.1016/j.eururo.2018.09.001. Epub 2018 Sep 26. PMID: 30268659.
Brown KF, Rumgay H, Dunlop C, Ryan M, Quartly F, Cox A, Deas A, Elliss-Brookes L, Gavin A, Hounsome L, Huws D, Ormiston-Smith N, Shelton J, White C, Parkin DM. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br J Cancer. 2018 Apr;118(8):1130-1141. doi: 10.1038/s41416-018-0029-6. Epub 2018 Mar 23. PMID: 29567982; PMCID: PMC5931106.
Löfling L, Bahmanyar S, Kieler H, Lambe M, Wagenius G. Temporal trends in lung cancer survival: a population-based study. Acta Oncol. 2022 May;61(5):625-631. doi: 10.1080/0284186X.2021.2013529. Epub 2021 Dec 10. PMID: 34889167.
Maconachie R, Mercer T, Navani N, McVeigh G; Guideline Committee. Lung cancer: diagnosis and management: summary of updated NICE guidance. BMJ. 2019 Mar 28;364:l1049. doi: 10.1136/bmj.l1049. Erratum in: BMJ. 2019 Apr 1;365:l1514. doi: 10.1136/bmj.l1514. PMID: 30923038.
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, Ogunbiyi OJ, Azevedo E Silva G, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP; CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018 Mar 17;391(10125):1023-1075. doi: 10.1016/S0140-6736(17)33326-3. Epub 2018 Jan 31. PMID: 29395269; PMCID: PMC5879496.
Hemminki J, Försti A, Hemminki A, Hemminki K. Survival trends in solid cancers in the Nordic countries through 50 years. Eur J Cancer. 2022 Nov;175:77-85. doi: 10.1016/j.ejca.2022.08.015. Epub 2022 Sep 9. PMID: 36096040.
Withrow DR, Nicholson BD, Morris EJA, Wong ML, Pilleron S. Age-related differences in cancer relative survival in the United States: A SEER-18 analysis. Int J Cancer. 2023 Jun 1;152(11):2283-2291. doi: 10.1002/ijc.34463. Epub 2023 Feb 23. PMID: 36752633.
Tichanek F, Försti A, Hemminki O, Hemminki A, Hemminki K. Survival in Lung Cancer in the Nordic Countries Through A Half Century. Clin Epidemiol. 2023 May 1;15:503-510. doi: 10.2147/CLEP.S406606. PMID: 37153073; PMCID: PMC10162394.
Lundberg FE, Ekman S, Johansson ALV, Engholm G, Birgisson H, Ólafsdóttir EJ, Mørch LS, Johannesen TB, Andersson TM, Pettersson D, Seppä K, Virtanen A, Lambe M, Lambert PC. Trends in lung cancer survival in the Nordic countries 1990-2016: The NORDCAN survival studies. Lung Cancer. 2024 Jun;192:107826. doi: 10.1016/j.lungcan.2024.107826. Epub 2024 May 22. PMID: 38795460.
Francisci S, Minicozzi P, Pierannunzio D, Ardanaz E, Eberle A, Grimsrud TK, Knijn A, Pastorino U, Salmerón D, Trama A, Sant M; EUROCARE-5 Working Group:. Survival patterns in lung and pleural cancer in Europe 1999-2007: Results from the EUROCARE-5 study. Eur J Cancer. 2015 Oct;51(15):2242-2253. doi: 10.1016/j.ejca.2015.07.033. Epub 2015 Sep 26. PMID: 26421826.
Bi JH, Tuo JY, Xiao YX, Tang DD, Zhou XH, Jiang YF, Ji XW, Tan YT, Yuan HY, Xiang YB. Observed and relative survival trends of lung cancer: A systematic review of population-based cancer registration data. Thorac Cancer. 2024 Jan;15(2):142-151. doi: 10.1111/1759-7714.15170. Epub 2023 Nov 20. PMID: 37986711; PMCID: PMC10788469.
Schuurman MS, Lemmens VEPP, Portielje JEA, van der Aa MA, Visser O, Dinmohamed AG. The cancer burden in the oldest-old: Increasing numbers and disparities-A nationwide study in the Netherlands, 1990 to 2019. Int J Cancer. 2024 Jan 15;154(2):261-272. doi: 10.1002/ijc.34705. Epub 2023 Sep 4. PMID: 37664984.
Schuurman MS, Lemmens VEPP, Portielje JEA, van der Aa MA, Visser O, Dinmohamed AG. The cancer burden in the oldest-old: Increasing numbers and disparities-A nationwide study in the Netherlands, 1990 to 2019. Int J Cancer. 2024 Jan 15;154(2):261-272. doi: 10.1002/ijc.34705. Epub 2023 Sep 4. PMID: 37664984.
Park SY, Lee JG, Kim J, Bae MK, Lee CY, Kim DJ, Chung KY. The influence of smoking intensity on the clinicopathologic features and survival of patients with surgically treated non-small cell lung cancer. Lung Cancer. 2013 Sep;81(3):480-486. doi: 10.1016/j.lungcan.2013.07.002. Epub 2013 Jul 26. PMID: 23896023.
Okamoto T, Suzuki Y, Fujishita T, Kitahara H, Shimamatsu S, Kohno M, Morodomi Y, Kawano D, Maehara Y. The prognostic impact of the amount of tobacco smoking in non-small cell lung cancer--differences between adenocarcinoma and squamous cell carcinoma. Lung Cancer. 2014 Aug;85(2):125-30. doi: 10.1016/j.lungcan.2014.06.006. Epub 2014 Jun 16. PMID: 24976334.
Bergman M, Fountoukidis G, Smith D, Ahlgren J, Lambe M, Valachis A. Effect of Smoking on Treatment Efficacy and Toxicity in Patients with Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022 Aug 25;14(17):4117. doi: 10.3390/cancers14174117. PMID: 36077654; PMCID: PMC9454993.
IARC. Cancer incidence in five continents. Editor. Lyon: IARC; 2002.
Hemminki K, Försti A, Hemminki A, Ljungberg B, Hemminki O. Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years. PLoS One. 2022 Jan 4;17(1):e0261124. doi: 10.1371/journal.pone.0261124. PMID: 34982793; PMCID: PMC8726478.
Patja K, Hakala SM, Boström G, Nordgren P, Haglund M. Trends of tobacco use in Sweden and Finland: do differences in tobacco policy relate to tobacco use? Scand J Public Health. 2009 Mar;37(2):153-60. doi: 10.1177/1403494808100277. Epub 2009 Jan 22. PMID: 19164430.
GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet. 2017 May 13;389(10082):1885-1906. doi: 10.1016/S0140-6736(17)30819-X. Epub 2017 Apr 5. Erratum in: Lancet. 2017 Oct 7;390(10103):1644. doi: 10.1016/S0140-6736(17)32559-X. PMID: 28390697; PMCID: PMC5439023.
Koskinen A, Hemminki O, Försti A, Hemminki K. Incidence and survival in laryngeal and lung cancers in Finland and Sweden through a half century. PLoS One. 2022 May 27;17(5):e0268922. doi: 10.1371/journal.pone.0268922. PMID: 35622857; PMCID: PMC9140270.
Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint A, Køtlum JE, Olafsdóttir E, Pukkala E, Storm HH. NORDCAN--a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010 Jun;49(5):725-36. doi: 10.3109/02841861003782017. PMID: 20491528.
Pukkala E, Engholm G, Højsgaard Schmidt LK, Storm H, Khan S, Lambe M, Pettersson D, Ólafsdóttir E, Tryggvadóttir L, Hakanen T, Malila N, Virtanen A, Johannesen TB, Larønningen S, Ursin G. Nordic Cancer Registries - an overview of their procedures and data comparability. Acta Oncol. 2018 Apr;57(4):440-455. doi: 10.1080/0284186X.2017.1407039. Epub 2017 Dec 11. Erratum in: Acta Oncol. 2018 Apr;57(4):565. doi: 10.1080/0284186X.2018.1425193. PMID: 29226751.
Larønningen S, Ferlay J, Beydogan H, Bray F, Engholm G, Ervik M. NORDCAN: Cancer incidence, mortality, prevalence and survival in the nordic countries. Association of the nordic cancer registries. Cancer Registry of Norway. 2022.
Muggeo VM. Estimating regression models with unknown break-points. Stat Med. 2003 Oct 15;22(19):3055-71. doi: 10.1002/sim.1545. PMID: 12973787.
Muggeo VMR. Segmented: An r package to fit regression models with broken-line relationships. R News. 2008;8:20-25.
Zitricky F, Koskinen AI, Hemminki O, Försti A, Hemminki A, Hemminki K. Survival in oral and pharyngeal cancers is catching up with laryngeal cancer in the NORDIC countries through a half century. Cancer Med. 2024 Jan;13(1):e6867. doi: 10.1002/cam4.6867. Epub 2024 Jan 2. PMID: 38164108; PMCID: PMC10807619.
Sachs E, Sartipy U, Jackson V. Sex and Survival After Surgery for Lung Cancer: A Swedish Nationwide Cohort. Chest. 2021 May;159(5):2029-2039. doi: 10.1016/j.chest.2020.11.010. Epub 2020 Nov 17. PMID: 33217414; PMCID: PMC8129733.
Solberg S, Nilssen Y, Brustugun OT, Grimsrud TK, Haram PM, Helbekkmo N, Helland Å, Hjelde HH, Jakobsen B, Møller B, Petersen M, Strand TE, Wahl SGF, Aanerud M, Fjellbirkeland L. Increase in curative treatment and survival of lung cancer in Norway 2001-2016. Eur J Epidemiol. 2019 Oct;34(10):951-955. doi: 10.1007/s10654-019-00536-z. Epub 2019 Jul 16. PMID: 31313073.
Probst HB, Hussain ZB, Andersen O. Cancer patient pathways in Denmark as a joint effort between bureaucrats, health professionals and politicians--a national Danish project. Health Policy. 2012 Apr;105(1):65-70. doi: 10.1016/j.healthpol.2011.11.001. Epub 2011 Dec 1. PMID: 22136810.
Menon U, Vedsted P, Zalounina Falborg A, Jensen H, Harrison S, Reguilon I, Barisic A, Bergin RJ, Brewster DH, Butler J, Brustugun OT, Bucher O, Cairnduff V, Gavin A, Grunfeld E, Harland E, Kalsi J, Knudsen AK, Lambe M, Law RJ, Lin Y, Malmberg M, Turner D, Neal RD, White V, Weller D. Time intervals and routes to diagnosis for lung cancer in 10 jurisdictions: cross-sectional study findings from the International Cancer Benchmarking Partnership (ICBP). BMJ Open. 2019 Nov 27;9(11):e025895. doi: 10.1136/bmjopen-2018-025895. PMID: 31776134; PMCID: PMC6886977.
Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, Peters S, Planchard D, Smit EF, Solomon BJ, Veronesi G, Reck M; ESMO Guidelines Committee. Electronic address: [email protected]. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Apr;34(4):358-376. doi: 10.1016/j.annonc.2022.12.013. Epub 2023 Jan 17. PMID: 36669645.
Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, Peters S, Planchard D, Smit EF, Solomon BJ, Veronesi G, Reck M; ESMO Guidelines Committee. Electronic address: [email protected]. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Apr;34(4):339-357. doi: 10.1016/j.annonc.2022.12.009. Epub 2023 Jan 23. PMID: 36872130.
Jakobsen E, Rasmussen TR, Green A. Mortality and survival of lung cancer in Denmark: Results from the Danish Lung Cancer Group 2000-2012. Acta Oncol. 2016 Jun;55 Suppl 2:2-9. doi: 10.3109/0284186X.2016.1150608. Epub 2016 Apr 8. PMID: 27056247.
Song MA, Benowitz NL, Berman M, Brasky TM, Cummings KM, Hatsukami DK, Marian C, O'Connor R, Rees VW, Woroszylo C, Shields PG. Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma. J Natl Cancer Inst. 2017 Dec 1;109(12):djx075. doi: 10.1093/jnci/djx075. PMID: 28525914; PMCID: PMC6059254.
Hemminki K, Zitricky F, Försti A, Kontro M, Gjertsen BT, Severinsen MT, Juliusson G. Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century. Blood Cancer J. 2024 Mar 14;14(1):44. doi: 10.1038/s41408-024-01033-7. PMID: 38480693; PMCID: PMC10937905.
Hemminki K, Zitricky F, Försti A, Silvennoinen R, Vangsted A, Hansson M. Large differencies in age-specific survival in multiple myeloma in the nordic countries. Blood Cancer J. 2024 Mar 11;14(1):43. doi: 10.1038/s41408-024-01026-6. PMID: 38467614; PMCID: PMC10928156.
Ji J, Sundquist K, Sundquist J, Hemminki K. Comparability of cancer identification among Death Registry, Cancer Registry and Hospital Discharge Registry. Int J Cancer. 2012 Nov 1;131(9):2085-93. doi: 10.1002/ijc.27462. Epub 2012 Mar 15. PMID: 22307919.
O'Dowd EL, Lee RW, Akram AR, Bartlett EC, Bradley SH, Brain K, Callister MEJ, Chen Y, Devaraj A, Eccles SR, Field JK, Fox J, Grundy S, Janes SM, Ledson M, MacKean M, Mackie A, McManus KG, Murray RL, Nair A, Quaife SL, Rintoul R, Stevenson A, Summers Y, Wilkinson LS, Booton R, Baldwin DR, Crosbie P. Defining the road map to a UK national lung cancer screening programme. Lancet Oncol. 2023 May;24(5):e207-e218. doi: 10.1016/S1470-2045(23)00104-3. PMID: 37142382.